Accelerating impact of long-acting technologies in low- and middle-income countries (LMICs)
Under this call, Unitaid is soliciting proposals to support development of long-actingproducts of medicines to treat and/or prevent diseases affecting LMICs, notably HIV, HIV coinfections/comorbidities, TB, and malaria, with broader consideration for management of antimicrobial resistance (AMR).
What should the proposals include?
- repurposing critical standard-of-care medicines into long-acting products, examples of such products may include injectables, implants, oral dosing technologies, or other;
- enabling sound commercialization to facilitate subsequent uptake and scale in LMICs for resulting products. Considerations include: capacity for adequate and quality-assured production; regulatory strategy for LMICs; licensure and pricing strategies that can facilitate introduction and broad access in LMICs.
Proposals submitted should clearly demonstrate the fit with the objectives set out above, the expected impact and value for money, as well as, the complementarity to similar projects in this area.
Applicants are encouraged to consider products that can be introduced in the market within three to five years (i.e. products that could be eligible for purchase by major funders and countries as relevant and supply capacity created to address demand sufficiently by the end of this timeframe).
Topics which are out of scope for this Call include:
a) proposals seeking the development of long-acting productss including new chemical entities (NCEs), or new indications for approved drugs, that require full clinical development prior to submission to regulatory approval;
b) proposals aiming to implement and/or deliver products at scale.
Additional information on Proposals:
Proposals that include more than one product, leveraging investments across product-categories, and collaborative partnerships including industry are welcomed. Proposed project governance should consider the integration of a scientific advisory board.